Boomers Should Not ...
Health Care: Drugs
Threshold Pharmaceuticals Inc. (THLD: NASDAQ)
$5.63 0.19 | 3.49%
05/23/13 - 04:00 PM ET
426.09K / 597.00K
Vol / Avg. Vol:5.39 / 5.44
Open / Prev. Close:5.30 - 5.64
Today's Range:3.95 - 9.28
52 Wk Range:32.54%
Performance YTD:TheStreet Rating:
Portfolios with THLD
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserBasement money
- UserStock Interests, Ideas & Re...
- UserMy Watch
- UserGopher Gold
- UserBlue Horseshoe loves Andeco...
- UserJARBAS ROCHA
Latest THLD Headlines from TheStreet
- 5 Stocks Poised for Breakouts 03.01.13 | 02:03 pm
- 4 Biotech Stocks Under $10 Moving Higher 02.20.13 | 09:02 pm
- 3 Biotech Stocks Under $10 Moving Higher 02.12.13 | 02:02 pm
- Stocks Continue to Climb as Companies Exceed Expectations 01.25.13 | 04:01 pm
- Biotech Stock Mailbag: Keryx, Sangamo, Threshold and Amarin 01.25.13 | 07:01 am
- Celgene's Abraxane: Two Month Survival Boost In Pancreatic Cancer Trial 01.22.13 | 06:01 pm
- 4 Biotech Stocks Spiking on Unusual Volume 01.08.13 | 02:01 pm
- 10 Best-Performing Biopharma Stocks of 2012 and Their 2013 Outlook 11.27.12 | 06:11 am
- Nate Sadeghi's 2012 Biotech Stock Report Card 11.26.12 | 07:11 am
- Celgene: Abraxane Boosts Pancreatic Cancer Survival 11.12.12 | 12:11 am
Press Releases for THLD
- SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Threshold Pharmaceuticals Inc. - PR Newswire 04.03.13 | 05:04 pm
- Threshold Pharmaceuticals Reports Second Quarter 2011 Financial And Operational Results - Business Wire 08.04.11 | 04:08 pm
- Threshold Pharmaceuticals Announces Initiation Of Clinical Trial Evaluating TH-302 In Combination With Bevacizumab At University Of Texas At San Antonio - Business Wire 07.25.11 | 09:07 am
- Threshold Pharmaceuticals Announces National Comprehensive Cancer Network (NCCN) Grant For Phase 1 Trial Of TH-302 In Combination With Pazopanib - Business Wire 07.06.11 | 08:07 am
- Threshold Pharmaceuticals Initiates Clinical Trial Evaluating TH-302 In Combination With Sunitinib - Business Wire 06.29.11 | 06:06 am
- Threshold Pharmaceuticals To Present At OneMedForum Conference - Business Wire 06.22.11 | 06:06 am
- Threshold Pharmaceuticals Announces Completion Of Patient Recruitment For Phase 2 TH-302 Pancreatic Cancer Study - Business Wire 06.21.11 | 04:06 pm
Partner Headlines for THLD
- A Journey To Add Biotech To The Portfolio - Seeking Alpha 05.18.13 | 02:05 am
- 3 Biotechs And The Feuerstein-Ratain Rule - Seeking Alpha 04.09.13 | 09:04 am
- Threshold Pharmaceuticals - A Derivative Trade On Ziopharm's Upcoming Data - Seeking Alpha 03.22.13 | 09:03 am
- UPDATE: Maxim Group Initiates Threshold Pharmaceuticals at Buy on Doxorubicin Potential - Benzinga 09.20.12 | 01:09 pm
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 09.18.12 | 09:09 am
- Morning Market Losers - Benzinga 09.17.12 | 09:09 am
- Buy Zalicus For A 120% Upside - Seeking Alpha 09.05.12 | 09:09 am
- Worthington INITIATED Buy and 3 Analyst-Initiated Stocks To Note - Wall St. Cheat Sheet 07.10.12 | 04:07 am
- Best Performing Stocks At 2012's Midpoint - Seeking Alpha 06.29.12 | 07:06 pm
- Healthcare Biz Recap: Express Scripts New Driver, Elan Pops - Wall St. Cheat Sheet 05.27.12 | 12:05 pm
